Biogen has stopped development of Denali-partnered Parkinson’s disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844